Compare PPSI & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPSI | SNTI |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1M | 31.5M |
| IPO Year | 2008 | 2021 |
| Metric | PPSI | SNTI |
|---|---|---|
| Price | $2.96 | $0.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 56.9K | ★ 228.0K |
| Earning Date | 04-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.31 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,627,000.00 | N/A |
| Revenue This Year | $2.71 | N/A |
| Revenue Next Year | $22.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.75 | N/A |
| 52 Week Low | $2.35 | $0.33 |
| 52 Week High | $6.29 | $2.88 |
| Indicator | PPSI | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 42.55 |
| Support Level | $2.75 | $0.33 |
| Resistance Level | $3.36 | $1.18 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 26.00 | 81.88 |
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets. The Company launched two new product platforms namely, PRYMUS, a new, mobile on-site power system concentrating on customers with requirements of 1-10 megawatts of mobile power and PowerCore, a residential and small commercial based primary generator system integrating a DC fast charger into one solution.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).